LUPHPOS – Lupus Physician’ Perspective On GlucocorticoidS- Survey

ERN ReCONNET is happy to extedn this important survey to all its members and friends.

You are invited to participate in the LUPHPOS survey (Lupus Physician’s Perspective on GlucocorticoidS-Survey)!

Corticoids (GC) play a key role in the treatment of systemic lupus erythematosus (SLE), especially in severe manifestations. Several studies highlight the harmful effects of chronic GC therapy, particularly the increased risk of irreversible organ damage. The lack of evidence on the use of GCs, combined with the inherent heterogeneity of the disease, means that the guidelines for the use of GCs in SLE are not very specific and it is not clear which daily dose of prednisone is the best to control disease activity without increasing the risk of irreversible damage. It remains unclear which daily prednisone dose is the best to control disease activity without increasing the risk of steroid-associated damage.

For these reasons, an independent group of young researchers (Spain, Italy, England, India and Sweden) led by Professor Marta Mosca with an interest in systemic lupus erythematosus (SLE), has developed a survey on the physician’s perspective on the use of corticosteroids in the treatment of SLE (LUPHPOS questionnaire: Lupus Physician’s Perspective on GlucocorticoidS-Survey).

We aim to help explore variations in GC prescribing practice between treatment centers, countries, and physicians and identify attitudes toward the use of steroids in physicians treating SLE adult patients.”

The link for the survey is here or you can use the QR code posted in this news.

The survey takes 5-8 min, it is in English, and it will be opened until the 1st of December.